You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Disc Medicines reported that its phase three Apollo study hit all primary and secondary endpoints and plans to launch the porphyria therapy next year; two phase two assets are expected to enter phase three studies.
Disc Medicine reported positive APOLLO Phase 3 results for bitopertin and plans an NDA resubmission by the end of 2026. Cash, cash equivalents and marketable securities totaled $682.8 million at September 30, 2026, funding is expected into 2030.
Disc Medicine’s APOLLO trial of bitopertin met all primary and secondary endpoints in EPP; NDA resubmission is planned by end of 2026, while approximately $486 million in October 2026 offering proceeds extend cash runway into 2030.
Disc Medicine, Inc. closed an underwritten offering on October 22, 2026 of 6,000,000 common shares at $75.00 per share, with expected net proceeds of approximately $422.4 million. Preliminary cash, cash equivalents and marketable securities were approximately $682.8 million as of September 30, 2026.
Disc Medicine announced positive Phase 3 APOLLO topline results for bitopertin in erythropoietic protoporphyria, meeting all primary and secondary endpoints, and plans to resubmit an NDA to the FDA by end of 2026 with a decision expected by mid-2027.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IRON
this stock
Disc Medicine, Inc.
|
$3.64B | +0.7% | — | — | 15.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Disc Medicines reported that its phase three Apollo study hit all primary and secondary endpoints and plans to launch the porphyria therapy next year; two phase two assets are expected to enter phase three studies.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IRON | +1.4% | +40.8% | +17.4% | -1.0% | +0.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.2% | +41.9% | +16.9% | -0.9% | -9.9% |
